REGENXBIO (NASDAQ:RGNX – Get Free Report) and Cue Biopharma (NASDAQ:CUE – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Analyst Recommendations
This is a summary of current recommendations and price targets for REGENXBIO and Cue Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| REGENXBIO | 1 | 3 | 9 | 1 | 2.71 |
| Cue Biopharma | 1 | 1 | 0 | 1 | 2.33 |
REGENXBIO currently has a consensus price target of $23.17, indicating a potential upside of 205.23%. Cue Biopharma has a consensus price target of $83.00, indicating a potential upside of 268.73%. Given Cue Biopharma’s higher probable upside, analysts plainly believe Cue Biopharma is more favorable than REGENXBIO.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| REGENXBIO | -112.58% | -220.07% | -46.04% |
| Cue Biopharma | -435.83% | -620.06% | -291.15% |
Volatility & Risk
REGENXBIO has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.62, indicating that its stock price is 162% more volatile than the S&P 500.
Insider and Institutional Ownership
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares REGENXBIO and Cue Biopharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| REGENXBIO | $170.44 million | 2.94 | -$193.88 million | ($3.79) | -2.00 |
| Cue Biopharma | $27.47 million | 5.95 | -$26.60 million | ($27.02) | -0.83 |
Cue Biopharma has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
REGENXBIO beats Cue Biopharma on 8 of the 14 factors compared between the two stocks.
About REGENXBIO
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
